Interestingly, some of these targets such as Tgfb1, Hras, Fgf2, and Ppargc1a have been implicated in cardiac hypertrophy suggesting that low-dose dasatinib indeed impacts genes that affect heart growth and remodeling [33–40]. The gene discussed is TGFB1; the disease is cardiac hypertrophy.